Cancers,
Journal Year:
2024,
Volume and Issue:
16(6), P. 1114 - 1114
Published: March 10, 2024
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
the
most
common
chronic
worldwide,
with
an
incidence
that
exponentially
increasing.
Hepatocellular
carcinoma
(HCC)
frequent
primary
tumor.
There
increasing
relationship
between
these
entities
due
to
potential
risk
of
developing
NAFLD-related
HCC
and
prevalence
NAFLD.
limited
evidence
regarding
prognostic
factors
at
diagnosis
HCC.
This
study
compares
prognosis
in
patients
NAFLD
against
other
etiologies.
It
also
evaluates
patients.
For
this
purpose,
a
multicenter
retrospective
was
conducted
involving
total
191
Out
total,
29
presented
The
extreme
gradient
boosting
(XGB)
method
employed
develop
reference
predictive
model.
Patients
showed
worse
compared
etiologies
Among
variables
worst
prognosis,
alcohol
consumption
had
greatest
weight
within
developed
In
comparison
studied
methods,
XGB
obtained
highest
values
for
analyzed
metrics.
conclusion,
consumption,
obesity,
cirrhosis,
clinically
significant
portal
hypertension
(CSPH)
exhibited
than
highly
efficient
model
assessment
Journal of Hepatology,
Journal Year:
2023,
Volume and Issue:
79(6), P. 1352 - 1365
Published: July 17, 2023
Recent
studies
have
highlighted
the
role
of
gut
microbiota
and
their
metabolites
in
non-alcoholic
fatty
liver
disease-associated
hepatocellular
carcinoma
(NAFLD-HCC).
We
aimed
to
identify
specific
beneficial
bacterial
species
that
could
be
used
prophylactically
prevent
NAFLD-HCC.
EBioMedicine,
Journal Year:
2024,
Volume and Issue:
100, P. 104952 - 104952
Published: Jan. 4, 2024
Gut
probiotic
depletion
is
associated
with
non-alcoholic
fatty
liver
disease-associated
hepatocellular
carcinoma
(NAFLD-HCC).
Here,
we
investigated
the
prophylactic
potential
of
Lactobacillus
acidophilus
against
NAFLD-HCC.
Alimentary Pharmacology & Therapeutics,
Journal Year:
2023,
Volume and Issue:
57(11), P. 1313 - 1325
Published: March 8, 2023
Summary
Background
and
Aims
Phase
III
trials
have
established
atezolizumab
plus
bevacizumab
as
the
novel
standard
of
care
for
patients
with
unresectable
hepatocellular
carcinoma
(HCC).
However,
these
raised
concerns
regarding
treatment
efficacy
in
non‐viral
HCC,
it
remains
unclear
whether
combination
immunotherapy
is
safe
effective
advanced
cirrhosis.
Methods
One
hundred
HCC
initiated
therapy
at
our
centre
between
January
2020
March
2022.
The
control
cohort
consisted
80
who
received
either
sorafenib
(
n
=
43)
or
lenvatinib
37)
systemic
treatment.
Results
Overall
survival
(OS)
progression‐free
(PFS)
were
significantly
longer
within
atezolizumab/bevacizumab
group
comparable
to
phase
data.
benefits
terms
increased
objective
response
rate
(ORR),
OS
PFS
consistent
across
subgroups,
including
(58%).
ROC‐optimised
neutrophil‐to‐lymphocyte
ratio
(NLR)
cut‐off
3.20
was
strongest
independent
predictor
ORR
PFS.
In
cirrhosis
Child–Pugh
B,
liver
function
better
preserved
immunotherapy.
Patients
B
showed
similar
but
shorter
compared
function.
Conclusions
Atezolizumab
good
safety
partially
a
real‐world
setting.
Moreover,
NLR
able
predict
may
guide
patient
selection.
Cell Death Discovery,
Journal Year:
2024,
Volume and Issue:
10(1)
Published: March 13, 2024
Abstract
Ferroptosis
is
an
iron
ion-dependent,
regulatory
cell
death
modality
driven
by
intracellular
lipid
peroxidation
that
plays
a
key
role
in
the
development
of
HCC.
Studies
have
shown
various
clinical
agents
(e.g.,
sorafenib)
ferroptosis
inducer-like
effects
and
can
exert
therapeutic
modulating
different
factors
pathway.
This
implies
targeting
tumor
may
be
very
promising
strategy
for
therapy.
In
this
paper,
we
summarize
prerequisites
defense
systems
occurrence
targets
drug-mediated
action
HCC,
differences
connections
between
other
programmed
deaths.
We
aim
to
theoretical
basis,
classical
inducers
research
progress
HCC
cells,
clued
treatment
regulating
network.
Further
investigation
specific
mechanisms
hepatocellular
carcinoma
interventions
at
stages
will
help
us
deepen
our
understanding
carcinoma,
with
view
providing
new
more
precise
preventive
as
well
measures
patients.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(1), P. 306 - 306
Published: Jan. 1, 2025
Nonalcoholic
fatty
liver
disease
(NAFLD),
recently
renamed
metabolic-associated
(MAFLD),
is
the
most
prevalent
worldwide.
It
associated
with
an
increased
risk
of
developing
hepatocellular
carcinoma
(HCC)
in
background
cirrhosis
or
without
cirrhosis.
The
prevalence
NAFLD-related
HCC
increasing
all
over
globe,
and
surveillance
NAFLD
cases
not
that
common.
In
present
review,
we
attempt
to
summarize
promising
treatments
clinical
trials
focused
on
NAFLD,
nonalcoholic
steatohepatitis
(NASH),
past
five
seven
years.
We
categorized
based
type
intervention.
Most
are
still
running,
only
a
few
completed
conclusive
results.
trial
NCT03942822,
25
mg/day
milled
chia
seeds
improved
condition.
Completed
NCT03524365
concluded
Rouxen-Y
gastric
bypass
(RYGB)
sleeve
gastrectomy
(SG)
results
histological
resolution
NASH
worsening
fibrosis,
while
NCT04677101
validated
sensitivity/accuracy
blood
biomarkers
predicting
fibrosis
stage.
Moreover,
empagliflozin
(NCT05694923),
curcuvail
(NCT06256926),
obeticholic
acid
(NCT03439254)
were
but
did
provide
However,
NCT03900429
reported
effective
improvement
by
at
least
one
stage,
activity
score
(NAS),
as
well
lipid
profile
patients
80
100
mg
MGL-3196
(resmetirom).
Funded
Madrigal
Pharmaceuticals,
Rezdiffra
(resmetirom),
used
NCT03900429,
first
FDA-approved
drug
for
treatment
NAFLD/NASH.
